JANUMET JANUMET SITA SITA SITA SITA SITA SITA PLUS SITA PLUS SITA PLUS SITA PLUS SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU SITAGLU MET SITAGLU MET SITAGLU MET SITAGLU MET SITAGLU MET SITAGLU MET TREVIA TREVIA TREVIA TREVIA TREVIA TREVIA TREVIA TREVIA TREVIA TREVIAMET TREVIAMET TREVIAMET TREVIAMET TREVIAMET TREVIAMET NUVIA NUVIA NUVIA NUVIA NUVIA NUVIA NUVIA NUVIA NUVIA SITAGEN SITAGEN SITAGEN SITAGEN-M BOUNTY BOUNTY BOUNTY BOUNTY BOUNTY BOUNTY BOUNTY BOUNTY BOUNTY SILO TAGIPMET TAGIPMET TAGIPMET SITA MET SITA MET TAGIP TAGIP TAGIP JANUVIA GLIPTIN GLIPTIN GLIPTIN PLUS GLIPTIN PLUS JANVIA-M JANVIA-M JENTIN MET JENTIN MET JUVIA-M PLUS QOSMET QOSMET

Dose: 100 mg
Single Dose: 100 (100)
Frequency: 24 hourly
Route: oral
Instructions: take with or without food. If drug bothers your stomach, try taking it with food._x000D_ In moderate renal insufficiency (CrCl >30 to 1.7 to 1.5 to 3.0 mg/dL in men and > 2.5 mg/dL in women) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of sitagliptin is 25 mg once daily

belongs to oral hypoglycemic. . The Molecular Weight of Sitagliptin is 523.32. It is weakly alkaline drug and Its pKa is 7.7.

Sitagliptin is contraindicated in conditions like Trauma,Insulin dependent diabetes mellitus,Type I diabetes mellitus,Diabetic ketoacidosis,Severe infections.

The severe or irreversible adverse effects of Sitagliptin, which give rise to further complications include Fever, Pancreatitis, Hypersensitivity reactions, Chills, Peeling & redness of skin.Sitagliptin produces potentially life-threatening effects which include Hypoglycemia, Hypoglycemia, Pancreatitis. which are responsible for the discontinuation of Sitagliptin therapy.The signs and symptoms that are produced after the acute overdosage of Sitagliptin include Tachycardia, Coma, Seizures, Drowsiness, Confusion, Hypoglycemia, Dizziness, Fainting, Sweating, Headache, Irritability, Tremor, Weakness.The symptomatic adverse reactions produced by Sitagliptin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Sore throat, Stomach upset, Stuffy nose.

Sitagliptin is primarily indicated in conditions like Type II diabetes mellitus.

No data regarding the interactions of Sitagliptin was found.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store .

Patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Sitagliptin should promptly be discontinued and appropriate management should be initiated. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD requiring hemodialysis or peritoneal dialysis. Use caution when used in conjunction with sulfonylureas; risk of hypoglycemia is increased. Monitor blood glucose closely; dosage adjustments of the sulfonylurea may be necessary. Safety and efficacy have not been established in children